Michael Mauro Discusses Therapy-Free CML Remission

Article

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses cessation of chronic myeloid leukemia (CML) treatment for therapy-free remission. 

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses cessation of chronic myeloid leukemia (CML) treatment for therapy-free remission. 

Mauro says patients with CML are often concerned about how long they have to stay on medication.

Recent Videos
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
blood cells on a yellow background

Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma

Tim Cortese
November 11th 2024
Article

Anitocabtagene autoleucel may be a promising CAR-T cell therapy option for patients with relapsed/refractory myeloma.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

CAR T-cells

Cilta-Cel May Outperform Standard Care for Relapsed, Refractory Myeloma

Jax DiEugenio
November 4th 2024
Article

An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

FDA Approved

Asciminib Gets Accelerated Approval for Ph+ CML

Brielle Benyon
October 29th 2024
Article

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.

Novel Drug Leads to Responses in Waldenström Macroglobulinemia

Novel Drug Leads to Responses in Waldenström Macroglobulinemia

Chris Ryan
October 27th 2024
Article

Among evaluable patients with Waldenström macroglobulinemia, the ORR was 77.8% with NX-5948.

© 2024 MJH Life Sciences

All rights reserved.